3rd Jun 2025 12:24
(Alliance News) - CRISM Therapeutics Corp on Tuesday said it has established a scientific advisory board as it prepares to submit a clinical trial application for its lead product, ChemoSeed.
Shares in CRISM Therapeutics were down 11% at 17.00 pence each in London on Tuesday afternoon. The stock remains up 79% over the past year.
The Surrey-headquartered pharmaceutical firm said the board will provide specific guidance on its upcoming registration grade phase 2 clinical trial for irinotecan ChemoSeed in patients with glioblastoma.
Glioblastoma is a type of cancer that originates in the brain.
ChemoSeed facilitates the local delivery of irinotecan directly to a brain tumour resection site, which allows the delivery of larger doses and reduces systemic concentrations. This alleviates traditional side effects for the patient.
The advisory board will be made up of Garth Cruickshank, an emeritus professor of Neurosurgery at the University of Birmingham, and Vinton Cheng, an associate clinical professor and honorary consultant in Medical Oncology at the University of Birmingham.
"We believe that CRISM has established a strong scientific advisory board, with both Vinton and Garth highly experienced in the field of neuro-oncology. They have significant expertise in the field of running successful clinical trials, regulation and academia and we are fortunate to be able to draw on this as the company prepares its CTA authorisation and subsequent phase II clinical trial for ChemoSeed in glioblastoma," said CRISM Chief Executive Officer Andrew Webb.
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Crism Thera